One‐year persistence of neutralizing anti‐SARS‐CoV‐2 antibodies in dialysis patients recovered from COVID‐19. Issue 4 (6th July 2021)

• Record Type: Journal Article
• Authors: Alfano, Gaetano; Fontana, Francesco; Morisi, Niccolò; Giaroni, Francesco; Mori, Giacomo; Guaraldi, Giovanni; Magistroni, Riccardo; Cappelli, Gianni
• Other Names: Mussini Cristina investigator.; Guaraldi Giovanni investigator.; Bacca Erica investigator.; Bedini Andrea investigator.; Borghi Vanni investigator.; Burastero Giulia investigator.; Carli Federica investigator.; Ciusa Giacomo investigator.; Corradi Luca investigator.; Cuomo Gianluca investigator.; Di Gaetano Margherita investigator.; Dolci Giovanni investigator.; Faltoni Matteo investigator.; Fantini Riccardo investigator.; Franceschi Giacomo investigator.; Franceschini Erica investigator.; Iadisernia Vittorio investigator.; Larné Damiano investigator.; Menozzi Marianna investigator.; Meschiari Marianna investigator.; Milic Jovana investigator.; Orlando Gabriella investigator.; Pellegrino Francesco investigator.; Raimondi Alessandro investigator.; Rogati Carlotta investigator.; Santoro Antonella investigator.; Tonelli Roberto investigator.; Tutone Marco investigator.; Volpi Sara investigator.; Yaacoub Dina investigator.; Cappelli Gianni investigator.; Magistroni Riccardo investigator.; Alfano Gaetano investigator.; Fontana Francesco investigator.; Mori Giacomo investigator.; Ascione Elisabetta investigator.; Damiano Francesca investigator.; Giovanella Silvia investigator.; Ligabue Giulia investigator.; Montani Martina investigator.; Morisi Niccolò investigator.; Melluso Andrea investigator.; Frisina Monica investigator.; Ferri Camilla investigator.; Ferrari Annachiara investigator.; Girardis Massimo investigator.; Andreotti Alberto investigator.; Biagioni Emanuela investigator.; Bondi Filippo investigator.; Busani Stefano investigator.; Chierego Giovanni investigator.; Scotti Marzia investigator.; Serio Lucia investigator.; Cossarizza Andrea investigator.; Bellinazzi Caterina investigator.; Borella Rebecca investigator.; De Biasi Sara investigator.; De Gaetano Anna investigator.; Fidanza Lucia investigator.; Gibellini Lara investigator.; Iannone Anna investigator.; Lo Tartaro Domenico investigator.; Mattioli Marco investigator.; Nasi Milena investigator.; Paolini Annamaria investigator.; Pinti Marcello investigator.;
• Is Part Of: Hemodialysis international. Volume 25:Issue 4(2021)
• Page Start: E53
• Page End: E56
• Publication Date: 2021-07-06
• Subjects: antibody -- COVID‐19 -- dialysis -- immunity -- Sars‐CoV‐2 -- vaccine; Hemodialysis -- Periodicals; Renal Dialysis -- Periodicals; Renal Dialysis -- Congresses; Hemodialysis, Home -- Congresses; 617.461059
• DOI: 10.1111/hdi.12963
• Languages: English
• ISSNs: 1492-7535

Abstract

Abstract: The immunological mechanisms that modulate immune response to SARS‐CoV‐2 infection remain elusive. Little is known on the magnitude and the durability of antibody response against COVID‐19. There is consensus that patients with immune dysfunction, such as dialysis patients, may be unable to mount a robust and durable humoral immunity after infections. Recent studies showed that dialysis patients seroconverted after COVID‐19, but data on the durability of the immune response are missing. We reported the data of a durable anti‐spike protein seroconversion after natural SARS‐CoV‐2 infection in three patients on hemodialysis with a mean age of 67.2 ± 13.8 years. A mean antibody titer of 212.6 ± 174.9 UA/ml (Liaison®, DiaSorin) was found after one year (range, 366–374 days) from the diagnosis of COVID‐19. In conclusion, this case series provided evidence that patients receiving hemodialysis who recovered from severe COVID‐19 were able to mount a long‐lasting immune response against SARS‐CoV‐2. Although the protective capacity of this long‐term immunity remains to be determined, these patients did not report signs of reinfection after recovery from COVID‐19.